OKYO Pharma (OKYO) Total Current Liabilities (2021 - 2025)

OKYO Pharma (OKYO) has 5 years of Total Current Liabilities data on file, last reported at $8.1 million in Q3 2025.

• Total Current Liabilities for Q3 2025 came in at $8.1 million, down 19.85% year-over-year; the trailing twelve-month figure through Sep 2025 was $8.1 million (down 19.85% YoY), and the FY2025 annual result was $9.2 million, up 24.34% from the prior year.
• Total Current Liabilities slipped to $8.1 million in Q3 2025 per OKYO's latest filing, from $9.2 million in the prior quarter.
• Over five years, Total Current Liabilities peaked at $10.1 million in Q3 2024 and troughed at $1.4 million in Q1 2022.
• A 5-year average of $6.7 million and a median of $7.7 million in 2024 frame the typical range for Total Current Liabilities.
• The sharpest annual moves came in 2022 and 2023: Total Current Liabilities retreated 20.74% in 2022, then jumped 436.3% in 2023.
• A 5-year view of Total Current Liabilities shows it stood at $1.7 million in 2021, then dropped by 20.74% to $1.4 million in 2022, then jumped by 514.52% to $8.3 million in 2023, then advanced by 20.91% to $10.1 million in 2024, then slipped by 19.85% to $8.1 million in 2025.
• Business Quant data shows OKYO's Total Current Liabilities at $8.1 million in Q3 2025, $9.2 million in Q1 2025, and $10.1 million in Q3 2024.